within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01C_AgentsAgainstLeishmaniasisAndTrypanosomiasis.P01CB01_MeglumineAntimonate;

model MeglumineAntimonate
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 9.722222222222224e-07,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.00020999999999999998,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00013000000000000002,
    k12 = 7.777777777777778e-07,
    k21 = 7.777777777777778e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>MeglumineAntimonate</td></tr><tr><td>ATC code:</td><td>P01CB01</td></tr><td>route:</td><td>intramuscular</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.21</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.05</td><td>L/kg/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Meglumine antimonate is a pentavalent antimonial compound historically used in the treatment of leishmaniasis, a parasitic disease. It is administered parenterally and is no longer the first-line therapy in many settings due to toxicity and the development of newer drugs.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adults with cutaneous leishmaniasis after intramuscular administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P01CB01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end MeglumineAntimonate;
